Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Shares issued

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Jun 10, 2022 12:50pm

151 Views

Post# 34747549

RE:Shares issued

Maybe consultants exercising early....

On January 1, 2022, options to purchase up to 4,325,000 common shares of the Company at a price of $0.17 per share for a period of three years were granted to consultants of the Company. 175,000 of these options were exercised during period.

lscfa wrote:

Must be exercise of options. Are employees exercising early because the warrants are worthless upon firing or exercising early to provide funds to co.?

At Jan 31

236,067,566

Feb Wrts exercised

12,258,960

248,326,526

Currently o/s

251,181,526

Difference =

2,855,000